Effects of debrisoquin on CSF and plasma HVA concentrations in man

J. W. Maas, S. A. Contreras, C. L. Bowden, Susan E Weintraub

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Data from animal studies indicate neuroleptic drugs act via their properties as antagonists of CNS dopamine (DA) receptors and this finding has led to the suggestion that alterations in CNS DA neuronal function are associated with psychotic disorders. Clinical investigations of this hypothesis, however, have been hindered by the lack the availability of a direct and relatively easily obtained index of CNS DA neuroanal activity. The work reported here was aimed at the development of such an index. Using a double blind design, human male subjects were given either placebo or debrisoquin, which is a monoamine oxidase inhibitor which does not penetrate brain. On the baseline day (no debrisoquin) and after 6 and 13 days of drug administration blood samples were obtained. In addition, for some patients CSF specimens were obtained via lumbar puncture on the baseline day and after 13 days of drug administration. It was found that debrisoquin produced a highly significant decrease in plasma homovanillic acid (HVA) concentrations whereas the concentrations of HVA in CSF were unchanged. In addition, it was found that the correlation between CSF and plasma HVA prior to debrisoquin was nonsignificant (r = 0.39, p = N.S., N = 10) whereas after 13 days of debrisoquin treatment the correlation was highly significant (r = 0.95, p < 0.1, N = 7). These findings suggest that the administration of debrisoquin produces a situation in which plasma HVA reflects CNS HVA production, and as such debrisoquin may be a useful tool for the clinical investigator who is interested in studying relationships in human subjects between CNS DA neuronal system function and psychopathological states or other disorders which may be mediated via brain DA systems.

Original languageEnglish (US)
Pages (from-to)2163-2170
Number of pages8
JournalLife Sciences
Volume36
Issue number22
DOIs
StatePublished - Jun 3 1985

Fingerprint

Debrisoquin
Homovanillic Acid
Plasmas
Dopamine
Brain
Monoamine Oxidase Inhibitors
Spinal Puncture
Dopamine Antagonists
Dopamine Receptors
Pharmaceutical Preparations
Psychotic Disorders
Antipsychotic Agents
Animals
Blood
Placebos
Research Personnel
Availability

ASJC Scopus subject areas

  • Pharmacology

Cite this

Effects of debrisoquin on CSF and plasma HVA concentrations in man. / Maas, J. W.; Contreras, S. A.; Bowden, C. L.; Weintraub, Susan E.

In: Life Sciences, Vol. 36, No. 22, 03.06.1985, p. 2163-2170.

Research output: Contribution to journalArticle

Maas, J. W. ; Contreras, S. A. ; Bowden, C. L. ; Weintraub, Susan E. / Effects of debrisoquin on CSF and plasma HVA concentrations in man. In: Life Sciences. 1985 ; Vol. 36, No. 22. pp. 2163-2170.
@article{f6a481dffcdb4129be373a8c22f68dda,
title = "Effects of debrisoquin on CSF and plasma HVA concentrations in man",
abstract = "Data from animal studies indicate neuroleptic drugs act via their properties as antagonists of CNS dopamine (DA) receptors and this finding has led to the suggestion that alterations in CNS DA neuronal function are associated with psychotic disorders. Clinical investigations of this hypothesis, however, have been hindered by the lack the availability of a direct and relatively easily obtained index of CNS DA neuroanal activity. The work reported here was aimed at the development of such an index. Using a double blind design, human male subjects were given either placebo or debrisoquin, which is a monoamine oxidase inhibitor which does not penetrate brain. On the baseline day (no debrisoquin) and after 6 and 13 days of drug administration blood samples were obtained. In addition, for some patients CSF specimens were obtained via lumbar puncture on the baseline day and after 13 days of drug administration. It was found that debrisoquin produced a highly significant decrease in plasma homovanillic acid (HVA) concentrations whereas the concentrations of HVA in CSF were unchanged. In addition, it was found that the correlation between CSF and plasma HVA prior to debrisoquin was nonsignificant (r = 0.39, p = N.S., N = 10) whereas after 13 days of debrisoquin treatment the correlation was highly significant (r = 0.95, p < 0.1, N = 7). These findings suggest that the administration of debrisoquin produces a situation in which plasma HVA reflects CNS HVA production, and as such debrisoquin may be a useful tool for the clinical investigator who is interested in studying relationships in human subjects between CNS DA neuronal system function and psychopathological states or other disorders which may be mediated via brain DA systems.",
author = "Maas, {J. W.} and Contreras, {S. A.} and Bowden, {C. L.} and Weintraub, {Susan E}",
year = "1985",
month = "6",
day = "3",
doi = "10.1016/0024-3205(85)90313-3",
language = "English (US)",
volume = "36",
pages = "2163--2170",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "22",

}

TY - JOUR

T1 - Effects of debrisoquin on CSF and plasma HVA concentrations in man

AU - Maas, J. W.

AU - Contreras, S. A.

AU - Bowden, C. L.

AU - Weintraub, Susan E

PY - 1985/6/3

Y1 - 1985/6/3

N2 - Data from animal studies indicate neuroleptic drugs act via their properties as antagonists of CNS dopamine (DA) receptors and this finding has led to the suggestion that alterations in CNS DA neuronal function are associated with psychotic disorders. Clinical investigations of this hypothesis, however, have been hindered by the lack the availability of a direct and relatively easily obtained index of CNS DA neuroanal activity. The work reported here was aimed at the development of such an index. Using a double blind design, human male subjects were given either placebo or debrisoquin, which is a monoamine oxidase inhibitor which does not penetrate brain. On the baseline day (no debrisoquin) and after 6 and 13 days of drug administration blood samples were obtained. In addition, for some patients CSF specimens were obtained via lumbar puncture on the baseline day and after 13 days of drug administration. It was found that debrisoquin produced a highly significant decrease in plasma homovanillic acid (HVA) concentrations whereas the concentrations of HVA in CSF were unchanged. In addition, it was found that the correlation between CSF and plasma HVA prior to debrisoquin was nonsignificant (r = 0.39, p = N.S., N = 10) whereas after 13 days of debrisoquin treatment the correlation was highly significant (r = 0.95, p < 0.1, N = 7). These findings suggest that the administration of debrisoquin produces a situation in which plasma HVA reflects CNS HVA production, and as such debrisoquin may be a useful tool for the clinical investigator who is interested in studying relationships in human subjects between CNS DA neuronal system function and psychopathological states or other disorders which may be mediated via brain DA systems.

AB - Data from animal studies indicate neuroleptic drugs act via their properties as antagonists of CNS dopamine (DA) receptors and this finding has led to the suggestion that alterations in CNS DA neuronal function are associated with psychotic disorders. Clinical investigations of this hypothesis, however, have been hindered by the lack the availability of a direct and relatively easily obtained index of CNS DA neuroanal activity. The work reported here was aimed at the development of such an index. Using a double blind design, human male subjects were given either placebo or debrisoquin, which is a monoamine oxidase inhibitor which does not penetrate brain. On the baseline day (no debrisoquin) and after 6 and 13 days of drug administration blood samples were obtained. In addition, for some patients CSF specimens were obtained via lumbar puncture on the baseline day and after 13 days of drug administration. It was found that debrisoquin produced a highly significant decrease in plasma homovanillic acid (HVA) concentrations whereas the concentrations of HVA in CSF were unchanged. In addition, it was found that the correlation between CSF and plasma HVA prior to debrisoquin was nonsignificant (r = 0.39, p = N.S., N = 10) whereas after 13 days of debrisoquin treatment the correlation was highly significant (r = 0.95, p < 0.1, N = 7). These findings suggest that the administration of debrisoquin produces a situation in which plasma HVA reflects CNS HVA production, and as such debrisoquin may be a useful tool for the clinical investigator who is interested in studying relationships in human subjects between CNS DA neuronal system function and psychopathological states or other disorders which may be mediated via brain DA systems.

UR - http://www.scopus.com/inward/record.url?scp=0021856935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021856935&partnerID=8YFLogxK

U2 - 10.1016/0024-3205(85)90313-3

DO - 10.1016/0024-3205(85)90313-3

M3 - Article

VL - 36

SP - 2163

EP - 2170

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 22

ER -